---
title: "Aligos Therapeutics ($ALGS): A Bold Move to Regain Nasdaq Compliance"
description: "Aligos Therapeutics executed a 1-for-25 reverse stock split effective August 19, 2024, to regain compliance with Nasdaq's minimum bid price. This move consolidates shares, boosting their value while m"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/213884447.md"
published_at: "2024-09-10T00:48:07.000Z"
---

# Aligos Therapeutics ($ALGS): A Bold Move to Regain Nasdaq Compliance

> Aligos Therapeutics executed a 1-for-25 reverse stock split effective August 19, 2024, to regain compliance with Nasdaq's minimum bid price. This move consolidates shares, boosting their value while maintaining market capitalization. It reflects the company’s commitment to continue operating on Nasdaq and developing therapies for liver and viral diseases. While the split increased short-term stock prices, investor perceptions may vary, affecting long-term confidence. Monitoring clinical trial progress and financial health will be key for investors moving forward.

**News Alert:**

Aligos Therapeutics, Inc. (ALGS), a clinical-stage biopharmaceutical company focusing on liver and viral diseases, recently executed a 1-for-25 reverse stock split. This strategic move, effective August 19, 2024, aims to boost the company’s stock price and regain compliance with the Nasdaq’s $1.00 minimum bid price requirement.

**Understanding the Reverse Stock Split**

In a 1-for-25 reverse stock split, every 25 shares of common stock are converted into one share. This action reduces the number of outstanding shares while increasing the price per share proportionally. While the reverse split doesn’t change the company’s market capitalization or a shareholder’s ownership percentage (except for minor adjustments for fractional shares), it can significantly impact investor sentiment.

**Why Did Aligos Take This Step?**

The primary reason for the reverse split was to ensure Aligos remains listed on the Nasdaq Capital Market. Failing to meet the minimum bid price requirement could lead to delisting, which often negatively affects a company’s reputation and access to capital. The reverse split signals Aligos’ determination to maintain its Nasdaq listing and continue its pursuit of developing novel therapeutics for liver and viral diseases.

**Investor Implications**

The reverse split’s immediate effect was a sharp increase in Aligos’ stock price. However, the long-term impact on investor confidence and share value remains to be seen. Some investors might perceive the reverse split as a sign of financial distress, while others might view it as a necessary step to ensure the company’s continued growth and development.

**Aligos’ Future Outlook**

Aligos Therapeutics’ bold move to regain Nasdaq compliance reflects the company’s commitment to its mission of addressing unmet medical needs in liver and viral diseases. With its strong focus on developing innovative therapeutics for MASH, hepatitis B, and coronaviruses, Aligos continues to be a company to watch in the biopharmaceutical space.

**Remember:** The reverse stock split is just one piece of the puzzle. Keep an eye on Aligos Therapeutics’ clinical trial progress, financial performance, and overall market sentiment to make informed investment choices.

### Related Stocks

- [ALGS.US - Aligos Therapeutics](https://longbridge.com/en/quote/ALGS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| UBS Initiates a Buy Rating on Aligos Therapeutics (ALGS) | In a report released yesterday, from UBS initiated coverage with a Buy rating on Aligos Therapeutics and a price target  | [Link](https://longbridge.com/en/news/271815294.md) |
| Aligos Therapeutics Appoints James Hassard as Chief Commercial Officer | Aligos Therapeutics Inc. has appointed James Hassard as Executive Vice President and Chief Commercial Officer, responsib | [Link](https://longbridge.com/en/news/272415292.md) |
| Aligos Therapeutics: Promising Developments in Liver Disease Programs and Strategic Pipeline Drive Buy Rating | Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating for Aligos Therapeutics, maintaining a $50 price t | [Link](https://longbridge.com/en/news/269413697.md) |
| Sio Capital Management LLC Increases Stock Position in Aligos Therapeutics, Inc. $ALGS | Sio Capital Management LLC increased its stake in Aligos Therapeutics by 85.9% in Q2, owning 5.50% of the company. Aligo | [Link](https://longbridge.com/en/news/268439986.md) |
| Aligos Therapeutics Showcases Positive Data at HEP-DART 2025 Meeting | Aligos Therapeutics presented positive data at the HEP-DART 2025 Meeting, highlighting synergistic fat mass loss with AL | [Link](https://longbridge.com/en/news/269383126.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.